Rapid Assessment and Treatment In Decompensated Aortic Stenosis (ASTRID-AS study)- A Pilot Study

Background

Acute decompensated aortic stenosis (ADAS) is common and associated with higher mortality, acute kidney injury (AKI) and longer hospital length of stay (LoS) compared to electively treated stable AS. The aim of this study was to assess the impact of a dedicated pathway that reduces time to transcatheter aortic valve implantation (TAVI) in ADAS, hypothesizing that LoS can be reduced without compromising patient safety.

Methods and results

Using a prospective, open label, cluster design, patients from 5 referring centres were allocated to the ASessment and TReatment In Decompensated Aortic Stenosis (ASTRID-AS) pathway where the diagnosis, referral, investigations and treatment of ADAS were prioritised and expedited. 15 hospitals remained on the conventional pathway that followed the same process, albeit according to a waiting list. The primary efficacy endpoint was hospital LoS and the secondary safety endpoint, a composite of death or AKI at 30 days post-TAVI.

58 conventional patients and 25 ASTRID-AS patients were included in this study. Time to TAVI in the conventional vs ASTRID-AS cohort was 22 (15-30) vs 10 (6-12) days; p < 0.001, respectively. Length of hospital stay was 24 (18-33) vs 13 (8-18) days; p < 0.001, respectively. 13.4 bed days were saved per patient using the ASTRID-AS pathway. Secondary safety endpoint occurred in 12 (20.7%) vs 1 (4.0%) patients; p = 0.093, respectively. Procedural complications were similar between the two cohorts.

Conclusion

A dedicated pathway for ADAS that shortens time to TAVI demonstrated reduced hospital LoS without compromising patient safety and a trend towards improving clinical outcomes.